Dr. Nowakowski on Using Patient Performance Score and Age for MCL Treatment

Grzegorz S. Nowakowski, MD
Published: Monday, Aug 28, 2017



Grzegorz S. Nowakowski, MD, assistant professor of medicine at Mayo Clinic, discusses the use of patient performance status and age to make treatment decisions for patients with mantle cell lymphoma (MCL).

The tools Nowakowski uses currently to determine treatment for patients with MCL is patient performance status and age. Age is an important factor; traditionally younger patients who are fit are treated with more aggressive chemotherapy followed by high-dose chemotherapy and autologous stem cell transplantation, he explains.

For elderly patients, physicians are more likely to administer less intensive options. The combination of bendamustine and rituximab (Rituxan) is frequently used, he adds. It is associated with improved progression-free survival versus R-CHOP in a randomized study. It is also well tolerated, Nowakowski concludes.
SELECTED
LANGUAGE


Grzegorz S. Nowakowski, MD, assistant professor of medicine at Mayo Clinic, discusses the use of patient performance status and age to make treatment decisions for patients with mantle cell lymphoma (MCL).

The tools Nowakowski uses currently to determine treatment for patients with MCL is patient performance status and age. Age is an important factor; traditionally younger patients who are fit are treated with more aggressive chemotherapy followed by high-dose chemotherapy and autologous stem cell transplantation, he explains.

For elderly patients, physicians are more likely to administer less intensive options. The combination of bendamustine and rituximab (Rituxan) is frequently used, he adds. It is associated with improved progression-free survival versus R-CHOP in a randomized study. It is also well tolerated, Nowakowski concludes.

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Community Practice Connections™: Advancing the Treatment of Bladder Cancers Using Evidence-Based Immuno-Oncology StrategiesJul 30, 20191.0
Medical Crossfire®: Where Are We Headed in the Treatment of Triple-Negative Breast Cancer?Jul 31, 20191.5
Publication Bottom Border
Border Publication
x